DEF: Lexicon Pharmaceuticals Seeks Stockholder Approval for Reverse Stock Split, Incentive Plan Amendments

Lexicon Pharmaceuticals is asking stockholders to approve a reverse stock split and amendments to its equity incentive plans at its upcoming annual meeting.

Summary

• Lexicon Pharmaceuticals is holding its annual meeting of stockholders online on June 2, 2025.
• Stockholders will vote on several proposals, including the election of two Class I directors, amendments to the 2017 Equity Incentive Plan and the 2017 Non-Employee Directors Equity Incentive Plan, and a reverse stock split.
• The proposed amendment to the 2017 Equity Incentive Plan would increase the total number of shares available for issuance by 20,000,000, bringing the total to 75,000,000 shares.
• The proposed amendment to the 2017 Non-Employee Directors Equity Incentive Plan would increase the total number of shares available for issuance by 2,000,000, bringing the total to 4,000,000 shares.
• The board of directors is seeking approval for a reverse stock split at a ratio between 1-for-10 and 1-for-50, with the final ratio to be determined by the board.
• Stockholders will also vote on an advisory resolution to approve executive compensation and to ratify the appointment of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2025.

Sentiment

Score: 6

Explanation: The document is primarily factual and procedural, with a neutral tone. The proposed actions are intended to improve the company's position, but there are also risks associated with them.

Positives

• The reverse stock split is intended to increase the per share market price of the common stock, potentially meeting Nasdaq listing requirements and improving the perception of the stock as an investment security.
• Increasing the number of authorized shares under the equity incentive plans allows the company to continue to attract and retain key employees and directors through stock-based compensation.
• The company received a favorable advisory vote on executive compensation at the 2024 annual meeting, indicating stockholder support for the company's approach to executive compensation.

Negatives

• The company received a written letter of non-compliance from Nasdaq on January 3, 2025, because the closing bid price of its common stock was below $1.00 for 31 consecutive business days.
• The reverse stock split could result in some stockholders owning odd lots of less than 100 shares, which may be more difficult to sell.
• The company did not achieve its objectives relating to INPEFA or ZYNQUISTA in 2024.

Risks

• The market price of the common stock may not increase in proportion to the reduction in the number of shares outstanding after a reverse stock split.
• A reverse stock split may be viewed negatively by some investors, potentially adversely impacting the market price per share.
• Future issuance of additional authorized shares of common stock could dilute future earnings per share, book value per share, and voting power of existing stockholders.
• The company may be unable to obtain necessary regulatory approvals for the issuance and sale of common stock under the equity incentive plans.

Future Outlook

The board of directors will determine whether, when, and at what ratio to effect a reverse stock split based on prevailing market conditions, the market price of the common stock, Nasdaq listing standards, and the number of authorized but unissued shares.

Management Comments

• Michael S. Exton, Ph.D., Chief Executive Officer: 'Thank you for your ongoing support of and continued interest in Lexicon Pharmaceuticals.'

Industry Context

The document relates to corporate governance matters common to publicly traded companies, particularly those in the biopharmaceutical industry that utilize equity compensation plans to attract and retain talent.

Comparison to Industry Standards

• The peer group of biopharmaceutical companies used for compensation decisions includes companies such as Altimmune, Inc., Dianthus Therapeutics, Inc., and Praxis Precision Medicines, Inc.
• The document mentions that many institutional investors have policies prohibiting them from holding lower-priced stocks in their portfolios, which is a common issue for companies with low share prices.
• The document mentions that many brokerage firms also have policies discouraging individual brokers from recommending lower-priced stocks to their customers or restricting or limiting the ability to purchase such stocks on margin, which is a common issue for companies with low share prices.

Management Changes

Related Party Transactions

• Invus, L.P. and its affiliates own approximately 49.7% of the outstanding common stock and have the right to designate a number of directors.
• Philippe J. Amouyal and Christopher J. Sobecki are managing directors of The Invus Group, LLC and designees of Invus, L.P.
• In March 2024, Lexicon entered into a purchase agreement with certain purchasers, including Invus, pursuant to which, among other things, Lexicon issued to such purchasers shares of its preferred stock in a private placement.

Stakeholder Impact

• Approval of the reverse stock split could impact shareholders by potentially increasing the stock price and improving market perception.
• Employees may be affected by changes to the equity incentive plans.
• The company's ability to meet Nasdaq listing requirements could impact all stakeholders.

Next Steps

• Stockholders will vote on the proposals at the annual meeting on June 2, 2025.
• The board of directors will determine whether to implement the reverse stock split and at what ratio.
• The company will file a certificate of amendment to its Sixth Amended and Restated Certificate of Incorporation if the reverse stock split is approved and implemented.

Key Dates

Keywords

reverse stock split, equity incentive plan, annual meeting, proxy statement, executive compensation, directors, stock options, restricted stock units, corporate governance, Lexicon Pharmaceuticals